Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

F Ayala de la Peña, B Ortiz-Muñoz, T Quintanar-Verdúguez, J D Santotoribio, S de la Cruz, J Trapé-Pujol, E Galve-Calvo, J M Augé-Fradera, J García-Gómez, Á González-Hernández, F Ayala de la Peña, B Ortiz-Muñoz, T Quintanar-Verdúguez, J D Santotoribio, S de la Cruz, J Trapé-Pujol, E Galve-Calvo, J M Augé-Fradera, J García-Gómez, Á González-Hernández

Abstract

The measurement of circulating tumour markers (TMs) for the diagnosis or monitoring of breast cancer has sometimes been considered of limited utility. In addition to the overinterpretation of irrelevant changes in marker levels, the characteristics of the patient, the disease or other pathologies that can modify them are often not considered in their evaluation. On the other hand, there are recent data on the relationship of TMs with molecular subtypes and on their prognostic value, the knowledge of which may improve their clinical utility. This consensus article arises from a collaboration between the Spanish Society of Laboratory Medicine (SEQCML) and the Spanish Society of Medical Oncology (SEOM). It aims to improve the use and interpretation of circulating TMs in breast cancer. The text summarizes the current knowledge and available evidence on the subject and proposes a series of recommendations mainly focussed on the indication, the frequency of testing and the factors that should be considered for correctly interpreting changes in the levels of TMs.

Keywords: Biomarkers; Breast neoplasms; Carcinoembryonic antigen; Tumor suppressor; p53.

Conflict of interest statement

The authors declare that they did not have any conflict of interest related with this project.

Figures

Fig. 1
Fig. 1
Example of changes in the levels of a tumour marker in the case of a benign (blue line) or malignant tumour (red line)

References

    1. Galceran J, Ameijide A, Carulla M, Mateos A, Quiros JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19:799–825. doi: 10.1007/s12094-016-1607-9.
    1. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52:345–351. doi: 10.1373/clinchem.2005.059832.
    1. Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30:1715–1724. doi: 10.1200/JCO.2012.42.8375.
    1. Gion M, Trevisiol C, Fabricio ASC. Appropriateness of tumor marker request: a case of study. Ann Transl Med. 2017;5:274. doi: 10.21037/atm.2017.06.19.
    1. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and prognostic significance of cancer antigen 15–3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients. Dis Markers. 2018;2018:9863092.
    1. Schrohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J, et al. Tumor markers: from laboratory to clinical utility. Mol Cell Proteomics. 2003;2:378–387. doi: 10.1074/mcp.R300006-MCP200.
    1. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:e11–79. doi: 10.1373/clinchem.2008.105601.
    1. Gaspar-Blázquez MJ, Trapé-Pujol J, Augé Fradera JM, Barco-Sánchez A, Carbonell-Muñoz R, Filella Pla X, et al. (2018) Recomendaciones para la optimización del uso de marcadores tumorales de utilización frecuente. Recomendación (2018) Lab Clin. 2019;12:38–52.
    1. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer—European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281–293. doi: 10.1159/000089260.
    1. Molina R, Auge JM, Escudero JM, Filella X, Zanon G, Pahisa J, et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol. 2010;31:171–180. doi: 10.1007/s13277-010-0025-9.
    1. Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA. Tumour Biol. 2018;40:1010428318776169. doi: 10.1177/1010428318776169.
    1. Trape J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer A, Rigo-Bonnin R, et al. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med. 2011;49:1605–1620. doi: 10.1515/CCLM.2011.694.
    1. Thompson J, Zimmermann W. The carcinoembryonic antigen gene family: structure, expression and evolution. Tumour Biol. 1988;9:63–83. doi: 10.1159/000217547.
    1. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36:41–48. doi: 10.1007/BF00690183.
    1. Colomer R, Aranda-Lopez I, Albanell J, Garcia-Caballero T, Ciruelos E, Lopez-Garcia MA, et al. Biomarkers in breast cancer: a consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018;20:815–826. doi: 10.1007/s12094-017-1800-5.
    1. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–5312. doi: 10.1200/JCO.2007.14.2364.
    1. Kabel AM. Tumor markers of breast cancer: new prospectives. J Oncol Sci. 2017;3:5–1. doi: 10.1016/j.jons.2017.01.001.
    1. Fu Y, Li H. Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis. Med Sci Monit. 2016;22:3154–3162. doi: 10.12659/MSM.896563.
    1. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1674. doi: 10.1093/annonc/mdz189.
    1. Duffy MJ, Walsh S, McDermott EW, Crown J. Biomarkers in breast cancer: where are we and where are we going? Adv Clin Chem. 2015;71:1–23. doi: 10.1016/bs.acc.2015.05.001.
    1. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)—Breast Cancer—Version 3.2019. 2019. . Accessed 5 Nov 2019
    1. Moschetti I, Cinquini M, Lambertini M, Levaggi A, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2016;2016:CD00768.
    1. Molina R, Bosch X, Auge JM, Filella X, Escudero JM, Molina V, et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol. 2012;33:463–474. doi: 10.1007/s13277-011-0275-1.
    1. Trape J, Sala M, Franquesa F, Ordeig JM, Soler-Bel JM, Bustamante E, et al. Clinical utility of determining tumor markers in patients with signs and symptoms of cancer. Clin Chem Lab Med. 2015;53:485–491. doi: 10.1515/cclm-2014-0410.
    1. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006;107:2545–2551. doi: 10.1002/cncr.22292.
    1. Di Gioia D, Stieber P, Schmidt GP, Nagel D, Heinemann V, Baur-Melnyk A. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. Br J Cancer. 2015;112:809–818. doi: 10.1038/bjc.2015.8.
    1. Goktas I, Cayvarli H. The role of (18)F-FDG PET/CT in evaluating elevated levels of tumor markers in breast cancer. Mol Imaging Radionucl Ther. 2018;27:3–9. doi: 10.4274/mirt.74436.
    1. Molina R, Escudero JM, Munoz M, Auge JM, Filella X. Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med. 2012;50:5–21. doi: 10.1515/cclm.2011.822.
    1. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015;33:2695–2704. doi: 10.1200/JCO.2015.61.1459.
    1. Yasasever V, Dincer M, Camlica H, Karaloglu D, Dalay N. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on “spiking” phenomena. Clin Biochem. 1997;30:53–56. doi: 10.1016/S0009-9120(96)00133-6.
    1. No authors. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843–2877
    1. Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006;6:220. doi: 10.1186/1471-2407-6-220.
    1. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer. 2004;11:389–395. doi: 10.1007/BF02968047.
    1. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer. 2007;7:36. doi: 10.1186/1471-2407-7-36.
    1. Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, et al. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 2008;10:R45. doi: 10.1186/bcr2096.
    1. Bast RC, Jr, Ravdin P, Hayes DF, Bates S, Fritsche H, Jr, Jessup JM, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878. doi: 10.1200/JCO.2001.19.6.1865.
    1. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) dagger. Ann Oncol. 2018;29:1634–1657. doi: 10.1093/annonc/mdy192.
    1. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer. 1999;35:47–53. doi: 10.1016/S0959-8049(98)00297-4.
    1. Melichar B. Biomarkers in the treatment of cancer: opportunities and pitfalls. Clin Chem Lab Med. 2013;51:1329–1333.
    1. Carney WP, Leitzel K, Ali S, Neumann R, Lipton A. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. 2007;9:207. doi: 10.1186/bcr1664.
    1. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005;7:R436–R443. doi: 10.1186/bcr1020.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다